| Protocol | Title |
|---|---|
| 40101 | Cyclophosphamide and Doxorubicin (CA)(4 vs 6 Cycles) Versus
Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in
Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase
III Randomized Study
Activation Date: 15-may-2002 |
| CALGB40503 | A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of
Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab (NSC
704865; IND 7921) for Women with Hormone Receptor-Positive Advanced
Breast Cancer
Activation Date: 22-may-2008 |
| E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide
followed by Paclitaxel with Bevacizumab or Placebo in Patients with
Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Activation Date: 02-nov-2007 |
| IBCSG2402 | A Phase III Trial Evaluating the Role of Ovarian Function Suppression
and the Role of Exemestane as Adjuvant Therapies for Premenopausal
Women with Endocrine Responsive Breast Cancer (SOFT)
Activation Date: 04-aug-2003 |
| IBCSG2502 | A Phase III Trial Evaluating the Role of Exemestane Plus GnRH
Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine
Responsive Breast Cancer (TEXT)
Activation Date: 04-aug-2003 |
| N063D | ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation
Study: A Randomised, Multi-centre, Open-label, Phase III Study of
Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination
in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Activation Date: 15-feb-2008 |
| PACT1 | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial
Assigning IndividuaLized Options for Treatment: The TAILORx Trial
Activation Date: 07-apr-2006 |
| S0221 | A Phase III Trial of Continuous Schedule AC + G Vs Q 2 Week Schedule
AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for
12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or
High-Risk Node Negative Breast Cancer
Activation Date: 14-nov-2003 |
| S0230 | Phase II Trial of LHRH Analog Administration During Chemotherapy to
Reduce Ovarian Failure Following Chemotherapy in Early Stage,
Hormone-Receptor Negative Breast Cancer
Activation Date: 06-jan-2005 |
| S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy
versus Maintaining Therapy for Metastatic Breast Cancer Patients who
Have Elevated Circulating Tumor Cell Levels at First Follow Up
Assessment
Activation Date: 01-oct-2006 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 03/11/10